Explore UAB

Colleges & Schools

Nutrition Obesity Research Center

Adipogenic and Metabolic Effects of Antipsychotic Drugs

Held On: Mon 7/11/2011 - Tue 7/12/2011
Location: Hilton Newark Airport
1170 Spring Street
Elizabeth, NJ 07201

Sponsors: UAB Nutrition Obesity Research Center

Organizing Committee

David A.David Allison, Ph.D.
UABJohn N.John Newcomer, MD
Miller School of Medicine, University of Miami Christoph C.Christoph Correll, MD
Albert Einstein College of MedicineJGary R.Gary Remington, MD Ph.D. FRCPC
Centre for Addiction and Mental Health (CAMH), CanadaElaine H.Elaine H. Morrato, DrPH MPH CPH
University of Colorado Denver

Overview

Though possessing many advantages, many Antipsychotic drugs (APDs) have a major liability in their ability to promote adiposity, obesity, and metabolic dysregulation in an already metabolically vulnerable population. The past decade has witnessed substantial research efforts aimed at quantifying, understanding, preventing, and alleviating these adverse effects and our goal is to provide a scientific update of these findings and discuss future research needs.

Schedule of Events

DateTimeSpeaker/ModeratorTopicVideo
Day 1 8:00 - 8:05 AM David B. Allison, Ph.D., University of Alabama at Birmingham Announcements/Business  
I. Magnitude and frequency of obesity, diabetes, and other metabolic disturbances among relevant patient populations.
8:05 - 8:10 AM David B. Allison, Ph.D. Overview by Moderator  
8:10 - 8:40 AM John Newcomer, MD, Miller School of Medicine, University of Miami Introduction and Scope of the Problem Watch Video
8:40 - 9:10 AM Marianne Ulcickas Yood, DSc, MPH, EpiSource, New York Adoption of Metabolic Monitoring & Risk Management Practices Watch Video
9:10 - 9:40 AM Karen Teff, Ph.D., University of Pennsylvania Atypical Antipsychotics: effects on post-prandial metabolism in healthy subjects, independent of weight gain or psychiatric disease  
9:40 - 10:05 AM All speakers led by Moderator Panel Discussion  
10:05 - 10:20 AM Break
II. The magnitude of the adverse metabolic effects, how they differ by drug, and drugs on the horizon with more benign metabolic profiles.
10:20 - 10:25 AM Julia M Gohlke, Ph.D., University of Alabama at Birmingham Overview by Moderator  
10:25 - 10:55 AM Ginger Nicol MD, Washington University Human studies of the effects of APDs on adiposity. Watch Video
10:55 - 11:25 AM David C. Henderson, MD, Harvard University Human studies of the effects of APDs on glucose metabolism and other metabolic syndrome features. Watch Video
11:25 - 11:55 AM Christopher J Lynch, Ph.D. Penn State University Metabolomics and metabolic phenotyping after exposure to side effect prone atypical antipsychotics Watch Video
11:55 - 12:25 PM Christoph Correll, MD, Albert Einstein College of Medicine Effects in children, adolescents, and first-break patients Watch Video
12:25 - 12:50 PM All speakers led by Moderator Panel Discussion  
12:25 - 2:00 PM Lunch
III. The biochemical, molecular, and mechanisms of these adverse APD effects.
2:00 - 2:05 PM Dilip V. Jeste, MD, University of California, San Diego Overview by Moderator  
2:05 - 2:35 PM Donard S. Dwyer, Ph.D., Louisiana State University Findings in invertebrate models: Basic mechanisms, neurotransmitter regulation, and neuroprotection. Watch Video
2:35 - 3:05 PM Marilyn Ader, Ph.D., University of Southern California Findings in mammalian models: Physiologic effects on endocrine regulation and dysregulation. Watch Video
3:05 - 3:15 PM Break
3:15 - 3:45 PM Henry Nasrallah, MD, University of Cincinnati The links between metabolic disorders and cognitive impairments Watch Video
3:45 - 4:25 PM Anil K. Malhotra, MD, Albert Einstein College of Medicine Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics. Watch Video
4:25 - 4:50 PM All speakers led by Moderator Panel Discussion  
Day 2 8:00 - 8:05 AM David B. Allison, Ph.D., University of Alabama at Birmingham Announcements/Business  
IV. The behavioral and energetic mechanisms of these adverse APD effects
8:05 - 8:10 AM Vicki L. Ellingrod Ringold, PharmD, University of Michigan Overview by Moderator  
8:10 - 8:45 AM Gary Remington MD Ph.D. FRCPC, Centre for Addiction and Mental Health (CAMH), Canada Rodent Models: a Viable Option? Watch Video
8:45 - 9:20 AM Vicki L. Ellingrod Ringold, PharmD, University of Michigan Antipsychotics, N-3 fatty acids, and pharmacogenetic factors Watch Video
9:20 - 9:55 AM Kimberly A. Brownley, Ph.D., University of North Carolina, Chapel Hill Human intake studies. Watch Video
9:55 - 10:25 AM All speakers led by Moderator Panel Discussion  
10:25 - 10:35 AM Break
V. The safety and efficacy of treatment and prevention strategies to reduce these adverse effects
10:35 - 10:40 AM Mary T. Weber, Ph.D., APRN, BC, PMHNP, University of Colorado Denver Overview by Moderator  
10:40 - 11:10 AM Rohan Ganguli, MD, University of Pittsburgh at Pittsburgh Lifestyle treatments to reduce adverse weight and metabolic effects Watch Video
11:10 - 11:40 AM Trino Baptista, MD, Ph.D., Los Andes University Medical School, Mérida, Venezuela Pharmacologic treatments to reduce adverse weight & metabolic effects Watch Video
11:40 - 12:10 PM Tony Cohn, MB ChB FRCPC, Department of Psychiatry, University of Toronto What are the metabolic benefits in switching antipsychotics and what are the risks? Watch Video
12:10 - 12:35 PM All speakers led by Moderator Panel Discussion  
12:35 - 1:45 PM Lunch
VI. Methodological issues
1:45 - 1:50 PM John Newcomer, M.D., Miller School of Medicine, University of Miami Overview by Moderator  
1:50 - 2:20 PM David B. Allison, Ph.D., University of Alabama at Birmingham Methodological issues in designing, analyzing, and interpreting randomized clinical trials of APD metabolic effects Watch Video
2:20 - 2:50 PM Elaine H. Morrato,DrPH, University of Colorado Denver Methodologic issues in epidemiologic and pharmacovigilance studies of APD metabolic effects. Watch Video
2:50 - 3:05 PM Break
VII. Translational Science & Personalized Medicine
3:05 - 3:10 PM Lydia Chwastiak, MD, Ph.D., Yale University Overview by Moderator  
3:10 - 3:40 PM Stephen Crystal, Ph.D., Rutgers University Broadened Use of Atypical Antipsychotics: Trends and Challenges for Policymakers, Clinicians, and Patients Watch Video
3:40 - 4:10 PM Deanna Kelly, PharmD, University of Maryland Metabolic and behavioral predictors of response and their implications for choice of treatment. Watch Video
4:10 - 4:35 PM All speakers led by Moderator Panel Discussion  

Speakers

  • David B. Allison, Ph.D. - UAB
  • Julia M Gohlke, Ph.D. - UAB
  • Marilyn Ader, Ph.D. - University of Southern California
  • Trino Baptista, MD, Ph.D. - Los Andes University Medical School, Mérida, Venezuela
  • Kimberly A. Brownley, Ph.D. - University of North Carolina, Chapel Hill
  • Lydia Chwastiak, MD, Ph.D. - Yale University
  • Tony Cohn, MB ChB FRCPC - Department of Psychiatry, University of Toronto
  • Christoph Correll, M.D. - Albert Einstein College of Medicine
  • Stephen Crystal, Ph.D. - Rutgers University
  • Donard S. Dwyer, Ph.D. - Louisiana State University
  • Vicki Ellingrod, PharmD - University of Michigan
  • Rohan Ganguli, MD - University of Pittsburgh at Pittsburgh
  • David C. Henderson, MD - Harvard University
  • Dilip V. Jeste, MD - University of California, San Diego
  • John M. Kane, MD - Albert Einstein College of Medicine
  • Deanna Kelly, PharmD - University of Maryland
  • Christopher J Lynch, Ph.D. - Penn State University
  • Anil K. Malhotra, MD - Albert Einstein College of Medicine
  • Elaine H. Morrato, DrPH MPH CPH - University of Colorado Denver
  • Henry Nasrallah, MD - University of Cincinnati
  • John Newcomer, MD - Miller School of Medicine, University of Miami
  • Ginger Nicol MD - Washington University
  • Gary Remington MD Ph.D. FRCPC - Centre for Addiction and Mental Health (CAMH), Canada
  • Vicki L. Ellingrod Ringold, PharmD - University of Michigan
  • Karen Teff, Ph.D. - University of Pennsylvania
  • Mary T. Weber, Ph.D., APRN, BC, PMHNP - University of Colorado Denver
  • Marianne Ulcickas Yood, DSc, MPH - EpiSource, New York

Contact Information:

Logistics: This email address is being protected from spambots. You need JavaScript enabled to view it.
Scientific: This email address is being protected from spambots. You need JavaScript enabled to view it.

Funded by:

Funding for this conference was made possible (in part) by (R13MH086166) from the National Institute of Mental Health (NIMH) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S Government.

Contributors:

Women, members of underrepresented minority groups and individuals with disabilities are strongly encouraged to apply.

Back to Top